Statistics from Altmetric.com
Heavy menstrual bleeding (HMB), which has become the preferred terminology to describe excess menstrual bleeding or menorrhagia,1 is prevalent among reproductive age women, negatively impacts quality of life, and represents a common reason for women to seek medical care and undergo gynaecological surgery. Although numerous comparative trials have demonstrated the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) in treating HMB, in general, these studies have been of 1 year or less in duration and have included small numbers of participants.2
Gupta and colleagues randomised 571 women in the UK who reported HMB to placement of an LNG-IUS or ‘usual medical treatment’ and followed the participants …
Competing interests AMK consults with Bayer, Merck, Teva and Agile and his institution has received research funding from Bayer. He also receives royalties from Up-To-Date e-textbook for chapters on contraception. He has also has received payment for development of Continuing Medical Education Programs regarding IUDs funded by Teva and Bayer.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.